|An integrated interdisciplinary approach to animal-free nanomaterial and chemical safety assessment.|
:: home :: :: project background :: :: sub projects :: :: work plan :: :: training :: :: apply here ::
The in3 project is funded by the EU's Marie Skłodowska-Curie Action - Innovative Training
Network (MSCA-ITN for short) that aims to drive the synergistic development and utilisation of in vitro and in silico
tools for human chemical and nanomaterial (NM) safety assessment. The
project will focus on differentiation of human induced Pluripotent Stem
Cells (hiPSC) to toxicologically relevant target tissues including; brain,
lung, liver and kidney. The tissues, from the same genetic backgrounds, will
be exposed to several compounds and the data generated will be used to
develop safety assessment approaches by integrating cheminformatics,
mechanistic toxicology and biokinetics into computational models. The
project will hire 15 PhD students to carry out these activities in a
coordinated and highly collaborative fashion. The scientists trained
within in3 will acquire a unique multidisciplinary skill set giving them a
competitive employment advantage in safety assessment sciences either in
industry, governmental bodies or academia.
Core scientific activities:
For individual projects click here.
in3 Consortium Beneficiaries (Hosts) and Partner Organisations
Medizinische Universität Innsbruck, Austria. Physiology and Medical Physics/Physiology, Ass. Prof. Paul Jennings. Coordinator.
Center for Alternatives to Animal Testing – EUROPE, Universität Konstanz, Germany. Dr. Mardas Daneshian